Imatinib mesylate discontinuation in patients with chronic myeloid leukemia who have received front-line imatinib mesylate therapy and achieved complete molecular response

Leukemia Research

Volumn 36, Issue 6, 2012, Pages 689-693

  Yhim, Ho Young ^a   Lee, Na Ri ^a,b   Song, Eun Kee ^a,b   Yim, Chang Yeol ^a,b   Jeon, So Yeon ^a   Shin, Seunghwan ^c   Kim, Jeong A ^c   Kim, Hee Sun ^d   Cho, Eun Hae ^e   Kwak, Jae Yong ^a,b  

^a Inje University   (South Korea)

^b Chonbuk National University Medical School   (South Korea)

^c The Catholic University of Korea College of Medicine   (South Korea)

^d Woosuk University   (South Korea)

^e Green Cross Reference Laboratory   (South Korea)

Author keywords

Chronic myeloid leukemia; Complete molecular response; Imatinib mesylate; Real time quantitative polymerase chain reaction

Indexed keywords

IMATINIB;

ADULT; AGED; ARTICLE; BCR ABL GENE; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; DRUG RESPONSE; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GENE; HUMAN; HYPERPIGMENTATION; LEUKEMIA RELAPSE; MALE; PRIORITY JOURNAL; PROGNOSIS; SCORING SYSTEM; SOKAL SCORE; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

ADULT; AGED; ANTINEOPLASTIC AGENTS; FEASIBILITY STUDIES; FEMALE; FOLLOW-UP STUDIES; FUSION PROTEINS, BCR-ABL; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; MOLECULAR DIAGNOSTIC TECHNIQUES; NEOADJUVANT THERAPY; PIPERAZINES; PYRIMIDINES; REMISSION INDUCTION; RETROSPECTIVE STUDIES; WITHHOLDING TREATMENT;

EID: 84862794931     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2012.02.011     Document Type: Article

References (21)

1. Hughes T.P., Hochhaus A., Branford S., Muller M.C., Kaeda J.S., Foroni L., et al. Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS). Blood 2010, 116:3758-3765.
2. Guo J.Q., Lin H., Kantarjian H., Talpaz M., Champlin R., Andreeff M., et al. Comparison of competitive-nested PCR and real-time PCR in detecting BCR-ABL fusion transcripts in chronic myeloid leukemia patients. Leukemia 2002, 16:2447-2453.
3. Quintas-Cardama A., Cortes J.E., Kantarjian H.M. Early cytogenetic and molecular response during first-line treatment of chronic myeloid leukemia in chronic phase: long-term implications. Cancer 2011, 117:5261-5270. 10.1002/cncr.26196.
4. Baccarani M., Saglio G., Goldman J., Hochhaus A., Simonsson B., Appelbaum F., et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 2006, 108:1809-1820.
5. Branford S., Seymour J.F., Grigg A., Arthur C., Rudzki Z., Lynch K., et al. BCR-ABL messenger RNA levels continue to decline in patients with chronic phase chronic myeloid leukemia treated with imatinib for more than 5 years and approximately half of all first-line treated patients have stable undetectable BCR-ABL using strict sensitivity criteria. Clin Cancer Res 2007, 13:7080-7085.
6. Cortes J., Talpaz M., O'Brien S., Jones D., Luthra R., Shan J., et al. Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate. Clin Cancer Res 2005, 11:3425-3432.
7. Kantarjian H., O'Brien S., Shan J., Huang X., Garcia-Manero G., Faderl S., et al. Cytogenetic and molecular responses and outcome in chronic myelogenous leukemia: need for new response definitions. Cancer 2008, 112:837-845.
8. Press R.D., Galderisi C., Yang R., Rempfer C., Willis S.G., Mauro M.J., et al. A half-log increase in BCR-ABL RNA predicts a higher risk of relapse in patients with chronic myeloid leukemia with an imatinib-induced complete cytogenetic response. Clin Cancer Res 2007, 13:6136-6143.
9. Verma D., Kantarjian H.M., Shan J., O'Brien S., Verma A., Jabbour E., et al. Sustained complete molecular response to imatinib in chronic myeloid leukemia (CML): a target worth aiming and achieving. ASH Annual Meeting Abstracts, vol. 114 2009, 505.
10. Rousselot P., Huguet F., Rea D., Legros L., Cayuela J.M., Maarek O., et al. Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years. Blood 2007, 109:58-60.
11. Ross D.D.M., Grigg A., Schwarer A., Arthur C., Loftus K., Mills A.K., et al. The majority of chronic myeloid leukaemia patients who cease imatinib after achieving a sustained complete molecular response (CMR) remain in CMR, and any relapses occur early. ASH Annual Meeting Abstracts, vol. 112 2008, 1102.
12. Cortes J., O'Brien S., Kantarjian H. Discontinuation of imatinib therapy after achieving a molecular response. Blood 2004, 104:2204-2205.
13. Mauro M.J., Druker B.J., Maziarz R.T. Divergent clinical outcome in two CML patients who discontinued imatinib therapy after achieving a molecular remission. Leuk Res 2004, 28(Suppl 1):S71-S73.
14. Merante S., Orlandi E., Bernasconi P., Calatroni S., Boni M., Lazzarino M. Outcome of four patients with chronic myeloid leukemia after imatinib mesylate discontinuation. Haematologica 2005, 90:979-981.
15. Mahon F.X., Rea D., Guilhot J., Guilhot F., Huguet F., Nicolini F., et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol 2010, 11:1029-1035.
16. Sokal J.E., Cox E.B., Baccarani M., Tura S., Gomez G.A., Robertson J.E., et al. Prognostic discrimination in "good-risk" chronic granulocytic leukemia. Blood 1984, 63:789-799.
17. Druker B.J., Guilhot F., O'Brien S.G., Gathmann I., Kantarjian H., Gattermann N., et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006, 355:2408-2417.
18. Deininger M. Hematology: curing CML with imatinib--a dream come true. Nat Rev Clin Oncol 2011, 8:127-128.
19. Jabbour E., Kantarjian H., O'Brien S., Shan J., Quintas-Cardama A., Faderl S., et al. The achievement of an early complete cytogenetic response is a major determinant for outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors. Blood 2011, 118:4541-4546. 10.1182/blood-2011-04-348110.
20. Saglio G., Kim D.W., Issaragrisil S., le Coutre P., Etienne G., Lobo C., et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 2010, 362:2251-2259.
21. Kantarjian H., Shah N.P., Hochhaus A., Cortes J., Shah S., Ayala M., et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2010, 362:2260-2270.